The stock of Anika Therapeutics Inc (NASDAQ: ANIK) has decreased by -11.10 when compared to last closing price of 17.11.Despite this, the company has seen a loss of -10.53% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-12 that Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Matt Hall – Director, Corporate Development & Investor Relations Cheryl Blanchard – President & Chief Executive Officer Steve Griffin – Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Jim Sidoti – Sidoti & Co. Mike Petusky – Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika’s Fourth Quarter and Year End Earnings Conference Call. At this time, all lines are in listen-only mode.
Is It Worth Investing in Anika Therapeutics Inc (NASDAQ: ANIK) Right Now?
Moreover, the 36-month beta value for ANIK is 0.75. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANIK is 14.13M and currently, short sellers hold a 2.64% of that float. On March 14, 2025, ANIK’s average trading volume was 70.62K shares.
ANIK’s Market Performance
The stock of Anika Therapeutics Inc (ANIK) has seen a -10.53% decrease in the past week, with a -14.36% drop in the past month, and a -11.72% fall in the past quarter. The volatility ratio for the week is 6.09%, and the volatility levels for the past 30 days are at 3.81% for ANIK. The simple moving average for the past 20 days is -11.67% for ANIK’s stock, with a -30.12% simple moving average for the past 200 days.
Analysts’ Opinion of ANIK
Many brokerage firms have already submitted their reports for ANIK stocks, with Barrington Research repeating the rating for ANIK by listing it as a “Outperform.” The predicted price for ANIK in the upcoming period, according to Barrington Research is $25 based on the research report published on November 01, 2024 of the previous year 2024.
Barrington Research, on the other hand, stated in their research note that they expect to see ANIK reach a price target of $24. The rating they have provided for ANIK stocks is “Outperform” according to the report published on August 14th, 2023.
ANIK Trading at -9.92% from the 50-Day Moving Average
After a stumble in the market that brought ANIK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.76% of loss for the given period.
Volatility was left at 3.81%, however, over the last 30 days, the volatility rate increased by 6.09%, as shares sank -13.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.34% lower at present.
During the last 5 trading sessions, ANIK fell by -10.53%, which changed the moving average for the period of 200-days by -38.40% in comparison to the 20-day moving average, which settled at $17.22. In addition, Anika Therapeutics Inc saw -7.59% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ANIK
Current profitability levels for the company are sitting at:
- -0.21 for the present operating margin
- 0.49 for the gross margin
The net margin for Anika Therapeutics Inc stands at -0.59. The total capital return value is set at -0.17. Equity return is now at value -20.21, with -15.13 for asset returns.
Based on Anika Therapeutics Inc (ANIK), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is -19.13.
Currently, EBITDA for the company is -11.23 million with net debt to EBITDA at 1.51. When we switch over and look at the enterprise to sales, we see a ratio of 1.14. The receivables turnover for the company is 5.79for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.88.
Conclusion
To wrap up, the performance of Anika Therapeutics Inc (ANIK) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
